Article
Australia clears first locally manufactured CAR-T programme for Phase II
Australia's Therapeutic Goods Administration has cleared the first locally manufactured CAR-T programme for a Phase II trial — a milestone that reframes the cell therapy hiring conversation across the next eighteen months.
The clearance lands six months earlier than the consensus forecast and signals that the domestic manufacturing capacity built during the 2024–2025 mRNA pivot has stabilised. For specialist recruiters, the operational consequence is direct: process scientists, GMP analysts, and quality leads with cell-therapy exposure are about to become a contested pool.
Where the demand will land
Three sites — Sydney, Melbourne, and Brisbane — are scaling staffing in lock-step. The trial design requires a 24-month manufacturing window, which means the headcount build is durable, not seasonal.
A 24-month manufacturing window means the headcount build is durable, not seasonal — the candidates moving now will define the next two cohorts.